News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Naviscan, Inc. Release: Low Dose PEM Results Presented at ECR 2012



3/1/2012 9:26:12 AM

VIENNA, AUSTRIA--(Marketwire - March 01, 2012) -

Presented today at the European Congress of Radiology (ECR) in Vienna, Austria, researchers from Boca Raton Regional Hospital in Florida showed that FDG dose for Positron Emission Mammography (PEM) may be reduced by up to 50% without impacting sensitivity. Several clinical cases utilizing an optimized dose were presented as part of this abstract.

"These results are extremely exciting and have immediately impacted my clinical practice," said Dr. Kathy Schilling, Medical Director of the Christine E. Lynn Women's Health & Wellness Institute at Boca Raton Regional Hospital. "In this era of cautiously using radiation, I have responded by lowering the dose by one half for my patients without compromising image quality and diagnostic ability."

PEM imaging shows the location as well as the metabolic phase of a lesion. This information is critical in determining whether a lesion is malignant and influences the course of treatment by providing an ability to distinguish between benign and malignant lesions, what researchers term "specificity." Recent studies have demonstrated that PEM has similar sensitivity and higher specificity than breast MRI. The scanner is the only FDA-cleared, CE-certified 3D Molecular Breast Imaging (MBI) device on the market with biopsy-guidance.

About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and is globally distributed in 34 countries. The Company is headquartered in San Diego, California and is the first to obtain FDA clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance.


Contact Information
Guillaume Bailliard
Executive Vice President
Naviscan, Inc.
Tel: +1.858.332.0941
Email Contact

Joleen Schultz
Naviscan Marketing Communications
321 Medical Launch
Tel: +1.858.455.5500
Email Contact

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES